TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2628637

Group type: EXPERIMENTAL
Intervention: Hand-held weights (2.27 kg) during running
Number of subjects: 10

Group type: COMPARATOR
Intervention: Hand-held weights (0, 0.45, 1.36 kg) during walking
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hand-held weights (2.27 kg or less) during walking
Number of subjects: 10
Study: 319269

Group type: EXPERIMENTAL
Intervention: Ephedrine sulfate and theophylline combination
Number of subjects: 16
Study: 31325161

Group type: EXPERIMENTAL
Intervention: Subcutaneous somatostatin (22 µg/kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intravenous somatostatin (22 µg/kg)
Number of subjects: 6
Study: 27873023

Group type: EXPERIMENTAL
Intervention: Acetylcysteine (AC) 3 × 100 mg for 3 weeks
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Azithromycin (AZ) body weight adjusted dose for 3 days
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combination of Acetylcysteine and Azithromycin at described doses
Number of subjects: 90
Study: 26415992

Group type: EXPERIMENTAL
Intervention: nintedanib+docetaxel
Number of subjects: 1307
Study: 23535165

Group type: EXPERIMENTAL
Intervention: Adaptive servo-ventilation (ASV) added to optimal medical management
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Optimal medical management alone (control group)
Number of subjects: 1200
Study: 21818634

Group type: EXPERIMENTAL
Intervention: Enteral immunonutrition (Group II)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard enteral nutrition (Group I)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Normal nutritional status (Group III)
Number of subjects: 72
Study: 18071727

Group type: EXPERIMENTAL
Intervention: Enoxaparin alone
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Combination treatment (prednisone, aspirin, progesterone)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Combination treatment vs Enoxaparin
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Treated groups (Enoxaparin and Combination)
Number of subjects: 170
Study: 16507072

Group type: EXPERIMENTAL
Intervention: Chamomile hydroalcoholic extract
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tea tree oil
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 2.5% NaOCl
Number of subjects: 40

Group type: COMPARATOR
Intervention: Distilled water (negative control)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 2.5% NaOCl + 17% EDTA (positive control)
Number of subjects: 40
Study: 15047684

Group type: EXPERIMENTAL
Intervention: Butter diet
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Cheese diet
Number of subjects: 14

Group type: COMPARATOR
Intervention: Milk diet
Number of subjects: 14
Study: 10767224

Group type: EXPERIMENTAL
Intervention: Threshold loading test (inspiratory and expiratory)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Histamine bronchial provocation test
Number of subjects: 36
Study: 9075507

Group type: COMPARATOR
Intervention: Lignocaine 300 mg alone
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Lignocaine 300 mg with fentanyl 100 micrograms
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Lignocaine 200 mg with fentanyl 100 micrograms
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 56
Study: 7924831

Group type: EXPERIMENTAL
Intervention: Antioxidants (cocktail of several antioxidants at high dosage)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lymphocyte photopheresis (treatment of lymphocytes with methoxypsoralen and UVA irradiation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group for lymphocyte photopheresis)
Number of subjects: 0
Study: 3555054

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (750 mg twice daily for seven days)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Doxycycline (100 mg twice daily for seven days)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 225

Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 225
Study: 28189366

Group type: EXPERIMENTAL
Intervention: ECP002A (oral formulation of Δ9-tetrahydrocannabinol)
Number of subjects: 24
Study: 27942550

Group type: EXPERIMENTAL
Intervention: Palifermin (60 μg/kg/day as an intravenous bolus once daily for 3 days before and 3 days after chemotherapy)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Chlorhexidine mouthwash (once daily for 3 days before and 3 days after chemotherapy)
Number of subjects: 90
Study: 24148140

Group type: EXPERIMENTAL
Intervention: Interventions designed to link those with SUDs to treatment
Number of subjects: 1441
Study: 22578757

Group type: EXPERIMENTAL
Intervention: Pertubation with lidocaine
Number of subjects: 26
Study: 20233982

Group type: EXPERIMENTAL
Intervention: Pharmacist-assisted medication reconciliation, inpatient pharmacist counseling, low-literacy adherence aids, and tailored telephone follow-up after discharge
Number of subjects: 862

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 862
Study: 18397986

Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sulfonylurea (SU) treatment
Number of subjects: 60
Study: 16816308

Group type: EXPERIMENTAL
Intervention: Supported employment (n = 75)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Traditional vocational services (n = 75)
Number of subjects: 150
Study: 14671225

Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 0
Study: 11004361

Group type: EXPERIMENTAL
Intervention: Intermittent bolus amnioinfusion (500 mL over 30 minutes, repeated if necessary)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Continuous amnioinfusion (500 mL over 30 minutes, then 3 mL per minute until delivery)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Both interventions (intermittent and continuous amnioinfusion)
Number of subjects: 65
Study: 8644646

Group type: EXPERIMENTAL
Intervention: Ibutilide
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Procainamide
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 1350596

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS and beta-blocker combination
Number of subjects: 207
Study: 6364879

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg oral administration)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 30016193

Group type: EXPERIMENTAL
Intervention: Pulsed Nd:YAG laser (high-intensity laser therapy) with exercise program, 600 J in two phases and 15 J to 10 points for a total of 750 J for each knee, thrice per week for 4 weeks.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pulsed Nd:YAG laser (high-intensity laser therapy) with exercise program, thrice per week for 4 weeks.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo laser with exercise program, same frequency and duration as the intervention group.
Number of subjects: 30
Study: 27959716

Group type: EXPERIMENTAL
Intervention: Celecoxib (mean daily dose: 209±37 mg)
Number of subjects: 24081

Group type: COMPARATOR
Intervention: Naproxen (mean daily dose: 852±103 mg)
Number of subjects: 24081

Group type: COMPARATOR
Intervention: Ibuprofen (mean daily dose: 2045±246 mg)
Number of subjects: 24081

Group type: EXPERIMENTAL
Intervention: Celecoxib (on-treatment analysis)
Number of subjects: 24081

Group type: COMPARATOR
Intervention: Naproxen (on-treatment analysis)
Number of subjects: 24081

Group type: COMPARATOR
Intervention: Ibuprofen (on-treatment analysis)
Number of subjects: 24081

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 24081
Study: 24343476

Group type: EXPERIMENTAL
Intervention: Aripiprazole (3.22 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Risperidone (0.6 mg/day)
Number of subjects: 60
Study: 22499474

Group type: EXPERIMENTAL
Intervention: Weekly EBP-structured case conference (Group A)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Didactic lecture about EBP (Group B)
Number of subjects: 94
Study: 19713265

Group type: EXPERIMENTAL
Intervention: Sugammadex (2 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neostigmine (50 microg/kg) plus glycopyrrolate (10 microg/kg)
Number of subjects: 0
Study: 18846435

Group type: EXPERIMENTAL
Intervention: Depot Medroxyprogesterone Acetate (DMPA)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate (LA)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Combined analysis of DMPA and LA
Number of subjects: 225
Study: 16126582

Group type: EXPERIMENTAL
Intervention: Automated data acquisition package of 12 lead ECG signals; QRS complex detector with accuracy level approximately 98.4%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Frequency-plane analysis using Discrete Fourier Transform (DFT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistical analysis of amplitude property
Number of subjects: 0
Study: 12092742

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 24

Group type: COMPARATOR
Intervention: Lisinopril
Number of subjects: 24
Study: 10643545

Group type: EXPERIMENTAL
Intervention: Morphine (5 mg for seven opioid-naïve patients and 3.75 mg for two patients on top of their regular oral dose of 7.5 mg q4 h)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 9
Study: 7768345

Group type: COMPARATOR
Intervention: Normal surface, eyes open
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal surface, eyes closed
Number of subjects: 0

Group type: COMPARATOR
Intervention: Foam surface, eyes open
Number of subjects: 0

Group type: COMPARATOR
Intervention: Foam surface, eyes closed
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total power calculated between 0 and 4Hz
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Slopes of logarithmically transformed data
Number of subjects: 0
Study: 2190436

Group type: EXPERIMENTAL
Intervention: Auranofin (Ridaura)
Number of subjects: 0
Study: 6107406

Group type: EXPERIMENTAL
Intervention: Regular aspirin
Number of subjects: 9

Group type: COMPARATOR
Intervention: Enteric-coated aspirin
Number of subjects: 9
Study: 30269650

Group type: EXPERIMENTAL
Intervention: Advance Care Planning programme
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 97
Study: 27876200

Group type: EXPERIMENTAL
Intervention: 4 Pillars™ Practice Transformation Program (intervention group)
Number of subjects: 10861

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10861
Study: 26021226

Group type: EXPERIMENTAL
Intervention: Mucositis (M)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Peri-implantitis (P)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Healthy (H)
Number of subjects: 75
Study: 23564915

Group type: EXPERIMENTAL
Intervention: Lixisenatide 20 µg
Number of subjects: 446

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 446
Study: 21332799

Group type: EXPERIMENTAL
Intervention: 1.6 g eicosapentaenoic acid (EPA) and 1.1 g docosahexaenoic acid (DHA) supplementation
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study: 19125875

Group type: EXPERIMENTAL
Intervention: Dexamethasone + intravenous metoclopramide + diphenhydramine
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo + intravenous metoclopramide + diphenhydramine
Number of subjects: 182
Study: 17223212

Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium (GIK) infusion at 2 ml/kg body weight per hour for 12 hours
Number of subjects: 889

Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 889
Study: 15321001

Group type: EXPERIMENTAL
Intervention: Inhaled insulin via AERx iDMS
Number of subjects: 17

Group type: COMPARATOR
Intervention: Subcutaneous insulin
Number of subjects: 17
Study: 11478827

Group type: COMPARATOR
Intervention: Fibre-free diet
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mixed fibre (pea and inuline)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Soy polysaccharide fibre
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All three diets
Number of subjects: 12
Study: 9544865

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hydrochlorothiazide-amiloride
Number of subjects: 50
Study: 8112188

Group type: EXPERIMENTAL
Intervention: Glipizide
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Glyburide
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 3170879

Group type: EXPERIMENTAL
Intervention: NaF dentifrice (1100 ppm F)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: F dentifrice followed by F rinse (FD/FR)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Older individuals with gingival recession
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bedtime F application
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo dentifrice (8 ppm F)
Number of subjects: 10
Study: 31518640

Group type: EXPERIMENTAL
Intervention: lncRNA regulators
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: lncRNA MSTRG.1056.2
Number of subjects: 2
Study: 31596802

Group type: EXPERIMENTAL
Intervention: Multimodal surgical-site injection (ropivacaine 200 mg, epinephrine 0.6 mg, and morphine 5 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No injection (control)
Number of subjects: 100
Study: 28329334

Group type: EXPERIMENTAL
Intervention: OBV/PTV/r + DSV + RBV for 12 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: DRV 800 mg QD
Number of subjects: 22

Group type: COMPARATOR
Intervention: DRV 600 mg BID
Number of subjects: 22
Study: 22831182

Group type: EXPERIMENTAL
Intervention: Low-Fat Diet (LF)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Low-Carbohydrate Diet (LC)
Number of subjects: 81
Study: 21693045

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Amoxycillin and clavulanic acid
Number of subjects: 420

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420
Study: 18043700

Group type: EXPERIMENTAL
Intervention: Multivitamin (MV) tablet
Number of subjects: 92
Study: 16807277

Group type: EXPERIMENTAL
Intervention: 8 mm-tip catheter
Number of subjects: 281

Group type: COMPARATOR
Intervention: ecRFA catheter
Number of subjects: 281
Study: 15476999

Group type: EXPERIMENTAL
Intervention: Education programme by a general practice assistant focusing on technical skills and coping with the disease
Number of subjects: 276

Group type: COMPARATOR
Intervention: Usual-care group
Number of subjects: 276
Study: 11238500

Group type: EXPERIMENTAL
Intervention: 75 g oral glucose
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 9535242

Group type: EXPERIMENTAL
Intervention: 25 microg/ml vancomycin added to PN
Number of subjects: 38

Group type: COMPARATOR
Intervention: No medication
Number of subjects: 38
Study: 7833191

Group type: EXPERIMENTAL
Intervention: Flucloxacillin (or clindamycin if allergic to penicillin)
Number of subjects: 473

Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 473
Study: 3404500

Group type: EXPERIMENTAL
Intervention: Condition of arousal
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Condition of relaxation
Number of subjects: 2
Study: 29768414

Group type: EXPERIMENTAL
Intervention: Low-dose autologous AdMSC (1x10^6 cells/kg)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: High-dose autologous AdMSC (4x10^6 cells/kg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 27261416

Group type: EXPERIMENTAL
Intervention: Balloon Sinuplasty
Number of subjects: 0

Group type: COMPARATOR
Intervention: Uncinectomy
Number of subjects: 0
Study: 25634162

Group type: EXPERIMENTAL
Intervention: Mouthrinses with sucrose or NaCl
Number of subjects: 10

Group type: COMPARATOR
Intervention: Mouthrinses without additives
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: All mouthrinses tested
Number of subjects: 10
Study: 24278924

Group type: EXPERIMENTAL
Intervention: Implants placed at the bone level (Group 0)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Implants placed 1 mm below the alveolar crest (Group 1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Implants placed 2 mm below the alveolar crest (Group 2)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Implants in groups 1 and 2 compared to Group 0
Number of subjects: 30
Study: 21929307

Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy (fludarabine and cyclophosphamide with rituximab)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Chemotherapy (fludarabine and cyclophosphamide without rituximab)
Number of subjects: 100
Study: 19099859

Group type: EXPERIMENTAL
Intervention: Carvedilol plus traditional regimen (digoxin, prednisone and/or diuretics)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Traditional regimen (digoxin, prednisone and/or diuretics)
Number of subjects: 21
Study: 11841719

Group type: EXPERIMENTAL
Intervention: Morphine-Adcon-L (M-ADL)
Number of subjects: 100
Study: 9800931

Group type: EXPERIMENTAL
Intervention: Norethisterone enanthate
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 8087777

Group type: EXPERIMENTAL
Intervention: Comorbidity assessment in cancer patients
Number of subjects: 1712

Group type: EXPERIMENTAL
Intervention: Data collection on current medications
Number of subjects: 1712

Group type: EXPERIMENTAL
Intervention: Pilot study results
Number of subjects: 1712

Group type: EXPERIMENTAL
Intervention: Full study planned
Number of subjects: 1712
Study: 2763389

Group type: EXPERIMENTAL
Intervention: Parietal cell vagotomy (PCV)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Truncal vagotomy (TV)
Number of subjects: 106
Study: 578772

Group type: EXPERIMENTAL
Intervention: Etozolin (400 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Etozolin (1200 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Vs (75 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Etozolin and Vs
Number of subjects: 8
Study: 27896440

Group type: EXPERIMENTAL
Intervention: Treosulfan intravenous (i.v.) 7000 mg/m2 d1 q4w
Number of subjects: 250

Group type: COMPARATOR
Intervention: Treosulfan oral (p.o.) 600 mg/m2 d1-28 q8w
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Treosulfan intravenous (i.v.)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Treosulfan oral (p.o.)
Number of subjects: 250
Study: 25702777

Group type: EXPERIMENTAL
Intervention: Human recombinant erythropoietin (HRE) 80,000 IU
Number of subjects: 600

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Human recombinant erythropoietin (HRE)
Number of subjects: 600
Study: 23417891

Group type: EXPERIMENTAL
Intervention: Taurolidine solution
Number of subjects: 112

Group type: COMPARATOR
Intervention: Heparin solution
Number of subjects: 112

Group type: COMPARATOR
Intervention: Standard group (Heparin)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Experimental group (Taurolidine)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 112
Study: 21131070

Group type: EXPERIMENTAL
Intervention: Digital inclusion program (computer learning workshop 'Idosos On‐Line')
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 42
Study: 19352154

Group type: EXPERIMENTAL
Intervention: Sprixx GJ device (Harbor Medical Inc., Santa Barbara, CA)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group (no device)
Number of subjects: 114
Study: 16919063

Group type: EXPERIMENTAL
Intervention: Olfactory hypersensitivity (OHS) in migraine patients
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (30 subjects)
Number of subjects: 74
Study: 15601961

Group type: EXPERIMENTAL
Intervention: Very-low-carbohydrate (VLC) diet
Number of subjects: 4

Group type: COMPARATOR
Intervention: Low-fat (LF) diet
Number of subjects: 4
Study: 11323348

Group type: EXPERIMENTAL
Intervention: Familiar instances (exemplars) from two categories (Experimental group)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Bird sounds (Control group)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Both groups (Experimental and Control)
Number of subjects: 82
Study: 9155592

Group type: EXPERIMENTAL
Intervention: Oral theophylline (240 mg)
Number of subjects: 28
Study: 8292702

Group type: COMPARATOR
Intervention: Halothane 1 MAC (group I, n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Isoflurane 1 MAC (group II, n = 10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Enoximone 0.5 mg/kg (after halothane and isoflurane)
Number of subjects: 20
Study: 29894374

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction intervention; 20 weekly, 1.5-hour sessions
Number of subjects: 44
Study: 27770787

Group type: EXPERIMENTAL
Intervention: Optimized virgin olive oil with high phenolic content (OVOO, 429 mg/Kg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Functional olive oil (FOO, 429 mg/Kg phenolic compounds, 389 mg/Kg triterpenic acids)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard virgin olive oil (VOO)
Number of subjects: 18
Study: 24430787

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention and treatment with voglibose or nateglinide
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Progressors (n=64)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Multivariate analysis
Number of subjects: 302
Study: 21948857

Group type: EXPERIMENTAL
Intervention: Urinary incontinence (including urge and stress incontinence)
Number of subjects: 5474

Group type: EXPERIMENTAL
Intervention: Volume of urine lost
Number of subjects: 5474

Group type: EXPERIMENTAL
Intervention: Presence of urinary symptoms
Number of subjects: 5474

Group type: EXPERIMENTAL
Intervention: Physical limitations
Number of subjects: 5474

Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 5474
Study: 20337620

Group type: EXPERIMENTAL
Intervention: C-MAC laryngoscope
Number of subjects: 31

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Glidescope laryngoscope
Number of subjects: 31
Study: 19922569

Group type: EXPERIMENTAL
Intervention: Check Your Drinking (CYD) screener
Number of subjects: 185

Group type: COMPARATOR
Intervention: No-intervention control group
Number of subjects: 185
Study: 16830374

Group type: EXPERIMENTAL
Intervention: Enzymatic detergent
Number of subjects: 260

Group type: COMPARATOR
Intervention: Chlorhexidine
Number of subjects: 260